How to Get Ozempic Privately in the UK

Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist originally developed by Novo Nordisk for type 2 diabetes management. It is administered as a once-weekly subcutaneous injection and is available in 0.25mg, 0.5mg, and 1mg doses.

In the UK, Ozempic holds marketing authorisation from the MHRA specifically for type 2 diabetes — not for weight management. For weight loss, the licensed semaglutide product is Wegovy, which uses a higher dose (up to 2.4mg weekly). However, due to supply constraints with Wegovy and the well-documented weight loss effects of Ozempic, many private prescribers have been prescribing Ozempic off-label for weight management.

NHS availability: On the NHS, Ozempic is primarily prescribed for type 2 diabetes when other treatments have been insufficient. It is not routinely available on the NHS for weight loss alone — Wegovy is the designated weight management product, and NHS access is limited by NICE guidelines and supply.

Private availability: Ozempic can be obtained through private prescriptions, provided a registered prescriber determines it is clinically appropriate. This has created a significant private market, with numerous clinics and telehealth services offering consultations and prescriptions.

It is worth noting that Novo Nordisk has asked prescribers to avoid prescribing Ozempic for weight loss to protect supply for diabetic patients. Whether private prescribers follow this guidance varies.

There are several legitimate routes to obtaining a private Ozempic prescription in the UK:

Private GP consultations: You can book a private consultation with a GP or specialist who prescribes GLP-1 agonists. During the consultation, the prescriber will assess your medical history, current medications, BMI, and overall health to determine whether semaglutide is appropriate. Expect a consultation fee of £50–150, separate from the medication cost.

Specialist weight management clinics: Dedicated weight management clinics — both in-person and online — have become increasingly common. These clinics typically employ prescribers who specialise in obesity medicine and may offer more comprehensive programmes that include dietary guidance, monitoring, and ongoing support alongside the prescription.

Online telehealth services: Numerous telehealth platforms now offer semaglutide prescriptions following an online consultation. These range from well-established services with thorough clinical assessments to more streamlined operations where the consultation may feel perfunctory. The quality of clinical oversight varies significantly.

Key requirements across all routes:

• •You will typically need a BMI of 30+ (or 27+ with weight-related comorbidities)
• •Blood tests may be required (HbA1c, thyroid function, renal function)
• •A medical history review to rule out contraindications (personal or family history of medullary thyroid carcinoma, MEN2 syndrome, pancreatitis, gastroparesis)
• •Ongoing monitoring, ideally including periodic blood tests and check-ins

The telehealth market for GLP-1 agonists has expanded rapidly in the UK. Here is what to look for and what to avoid:

Legitimate online services should:

• •Be registered with the General Pharmaceutical Council (GPhC) if dispensing medication
• •Employ prescribers registered with the General Medical Council (GMC) or equivalent body
• •Conduct a genuine clinical assessment — not just a tick-box questionnaire
• •Request relevant blood tests or recent test results
• •Have a clear complaints procedure and clinical governance framework
• •Provide ongoing monitoring and support, not just a one-off prescription

Red flags to watch for:

• •Services that guarantee a prescription before any consultation
• •No requirement for medical history or blood tests
• •Prescribers who are not identifiable or verifiable on the GMC register
• •Unusually low prices that may indicate counterfeit medication
• •No follow-up or monitoring offered
• •Medication shipped from outside the UK without proper import licensing

Well-regarded telehealth platforms typically charge a consultation fee plus the cost of medication, and will include at least some level of clinical monitoring. The total monthly cost through these services generally falls in the £150–300 range depending on the dose and the level of support included.

Always verify that any online pharmacy you use is listed on the GPhC register and displays the EU common logo (or UK equivalent) for online medicine sellers.

Private semaglutide treatment in the UK involves several cost components:

Consultation fees: Initial consultations typically cost £50–150, with follow-up consultations ranging from £30–80. Some services bundle consultation fees into the monthly medication cost.

Medication costs: The cost of Ozempic itself varies by dose and supplier: - 0.25mg/0.5mg pen (initiation dose): £80–150 - 1mg pen: £150–250 - Wegovy (if available) at higher doses can cost more

Monthly total: Most patients can expect to pay £150–300 per month for private semaglutide treatment, including medication and basic clinical oversight. Premium services with more intensive support may charge more.

Blood tests: Some clinics include blood tests in their fees; others require you to arrange them separately. Private blood panels relevant to GLP-1 treatment typically cost £50–120.

Factors that affect cost:

• •Dose escalation: You will start on a lower dose and increase over time, so costs may rise as your dose increases
• •Supply and demand: During periods of shortage, prices tend to increase
• •Service level: Basic prescription-only services cost less than comprehensive weight management programmes
• •Brand: Wegovy (the weight-loss-specific brand) may cost more than Ozempic when available

Insurance: Some private health insurance policies may cover weight management treatments, but coverage for GLP-1 agonists specifically is inconsistent. Check with your insurer before assuming coverage.

Not everyone is a suitable candidate for semaglutide. Understanding the eligibility criteria and medical considerations is essential before seeking a private prescription.

Typical eligibility criteria:

• •BMI ≥ 30 kg/m² (obese), or BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea
• •Age 18 or over
• •No contraindications (see below)
• •Willingness to make concurrent lifestyle changes (diet, exercise)

Contraindications — who should NOT take semaglutide:

• •Personal or family history of medullary thyroid carcinoma (MTC)
• •Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• •History of pancreatitis (relative contraindication — requires careful assessment)
• •Severe gastroparesis or other severe gastrointestinal disorders
• •Pregnancy or planning pregnancy (semaglutide must be stopped at least 2 months before conception)
• •Breastfeeding
• •Type 1 diabetes (semaglutide is not indicated and could be dangerous)

Common side effects to be aware of:

• •Nausea (very common, particularly during dose escalation — usually improves over time)
• •Vomiting, diarrhoea, constipation
• •Reduced appetite (this is the intended effect but can occasionally be excessive)
• •Injection site reactions
• •Fatigue and dizziness during initial treatment

Rare but serious risks:

• •Pancreatitis (seek immediate medical attention for severe abdominal pain)
• •Gallbladder problems
• •Hypoglycaemia (mainly in combination with insulin or sulfonylureas)
• •Potential thyroid C-cell tumour risk (observed in animal studies)

Before pursuing a private Ozempic prescription, consider the following practical advice:

1. Determine whether you genuinely need pharmacological intervention. If your BMI is under 27 and you have no weight-related health conditions, lifestyle modifications (nutrition, exercise, sleep optimisation) should be your first approach. GLP-1 agonists are powerful medications, not lifestyle accessories.

2. Understand the commitment. Semaglutide works whilst you take it. Research consistently shows that weight regain occurs after discontinuation unless significant lifestyle changes have been made and maintained. Plan for the long term, not a quick fix.

3. Choose your prescriber carefully. A thorough initial assessment, including blood tests and a genuine medical history review, is a sign of good clinical practice. Services that seem too quick or too easy should raise concerns.

4. Consider Wegovy vs Ozempic. If your primary goal is weight loss rather than diabetes management, Wegovy is the specifically licensed product and uses an optimised dosing schedule. Ask your prescriber about availability.

5. Budget realistically. At £150–300 per month, private semaglutide treatment is a significant ongoing expense. Factor in the potential duration of treatment — many patients take it for a year or more.

6. Explore NHS options first. Speak with your NHS GP about whether you might qualify for GLP-1 agonist treatment through the NHS, particularly if you have type 2 diabetes or meet the criteria for specialist weight management services.

*This guide is for educational purposes only. Always consult a qualified healthcare professional before starting any medication.*